Ardea Biosciences, Inc.
4939 Directors Place
San Diego,
CA 92121
Phone: 858-652-6500
Fax: 858-652-0760
Web Site: http://www.ardeabiosciences.com
| REUTERS ABRIDGED BUSINESS SUMMARY | |
| Ardea Biosciences, Inc., a biotechnology company, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV), cancer, and inflammatory diseases in the United States. The companys lead product candidate includes RDEA594, a product for the treatment of hyperuricemia and gout. Its other products comprise RDEA806 for the treatment of patients with HIV; and RDEA427, a second-generation NNRTI for the treatment of HIV, in a human micro-dose pharmacokinetic study. Ardea Biosciences is evaluating RDEA119, a non-ATP EK inhibitor, in a Phase I/II study in combination with sorafenib and as a single agent in a Phase I study, both in advanced cancer patients. It also develops RDEA436 for the treatment of inflammation. The company is based in San Diego, California. |
|
| Key Statistics | More from Reuters
Expanded Business Description |
| |
| REUTERS ABRIDGED FINANCIAL SUMMARY | |
| | Pay | Exercised | Dr. Barry D. Quart Pharm.d., 51
Chief Exec. Officer, Pres |
$
563.00K |
$
194.00K | Mr. John W. Beck C.P.A., 49
Chief Financial Officer, Principal Accounting Officer and Sr. VP of Fin. & Operations |
$
236.00K | N/A | Ms. Kimberly J. Manhard , 49
Sr. VP of Regulatory Affairs and Operations |
$
365.00K | N/A | Mr. Christopher W. Krueger J.D., MBA., 41
Chief Bus. Officer and Sr. VP |
$
352.00K | N/A | Dr. Colin E. Rowlings Ph.d., 45
Sr. VP of Pharmaceutical Sciences |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
Help
0.45 (3.21%) 
Profile
Reuters offers more in-depth
